

BIBLIOGRAPHY

1. Joint Commission on Accreditation of Healthcare Organizations. (2001). *Pain Standards for 2001*. www.jcaho.org/standard/pm.html.
2. Joint Commisiion on Accreditation of Healthcare Organizations. *Pain Management Standards*. Referenced from the Comprehensive Accreditation Manual for Hospitals, Update 3, 1999.
3. Federation of State Medical Boards of the United States, Inc. (1998). *Model Guidelines for the Use of Controlled Substances for the Treatment of Pain*.
4. American Academy of Pain Medicine, American Pain Society and American Society of Addiction Medicine. (2001). *Definitions Related to the Use of Opioids for the Treatment of Pain..*
5. American Academy of Pain Medicine and American Pain Society. (1997). *The Use of Opioids for the Treatment of Chronic Pain*.
6. Jacox A, Carr DB, Payne R. (1994). New Clinical-Practice Guidelines for the Management of Pain in Patients with Cancer. *N Eng J Med* 330 (9):651-655.
7. Joranson DE, Gilson AM, Ryan KM, Maurer MA, Nischik JA, Nelson JM. *Achieving Balance in Federal & State Pain Policy. A Guide to Evaluation*. The Pain and Policy Studies Group University of Wisconsin Comprehensive Cancer Center. (2000). <http://www.medsch.wisc.edu/painpolicy/eguide2000/index.html>
8. U.S. Department of Health and Human Services, Food and Drug Administration. Federal Register, Vol. 66, No. 79. p. 20589, Tuesday, April 24, 2001. *21 CFR Parts 50 and 56. Additional Safeguards for Children in Clinical Investigations of FDA-Regulated Products*. <http://www.fda.gov/ohrms/dockets/98fr/042401a.htm>
9. Food and Drug Administration. *Frequently Asked Questions on Pediatric Exclusivity (505A), The Pediatric "Rule", and Their Interaction*. <http://www.fda.gov/cder4/pediatric/faqs.htm>.
10. U.S. Department of Health and Human Services, Food and Drug Administration. Federal Register, Vol. 63, No. 231, p. 66632, Wednesday, December 2, 1998. *21 CFR Parts 201, 312, 314, and 601. Regulations Requiring Manufacturers to Assess the Safety and Effectiveness of New Drugs and Biological Products in Pediatric Patients; Final Rule*. <http://www.fda.gov/ohrms/dockets/98fr/120298c.txt>
11. U.S. Department of Health and Human Services, Food and Drug Administration. Draft Guidance for Industry. *Recommendations for Complying With the Pediatric*

Rule (21 CFR 314.55(a) and 601.27(1)). November 2000.

<http://www.fda.gov/cder/guidance/3578dft.htm>

12. U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for Industry. Qualifying for Pediatric Exclusivity Under Section 505A of the Federal Food, Drug, and Cosmetic Act. September, 1999.
<http://www.fda.gov/cder/guidance/2891fnl.htm>
13. 45 CFR Subtitle A (10-1-97 Edition). *Subpart D-Additional Protections for Children Involved as Subjects in Research.*
14. U.S. Department of Health and Human Services, Food and Drug Administration. Federal Register, December 13, 2001. *21 CFR Part 201. Specific Requirements on Content and Format of Labeling for Human Prescription Drugs; Revision of "Pediatric Use" Subsection In the Labeling.*
<http://www.fda.gov/cder/pediatric/frde1394ped.htm>.